Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow
Best PFS In Second Line Setting
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.
